Beyond chemotherapy: targeted therapies in ovarian cancer (original) (raw)

• Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108 (2005).
  Article PubMed Google Scholar
• Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).
  Article PubMed Google Scholar
• Dinh, P., Harnett, P., Piccart-Gebhart, M. J. & Awada, A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit. Rev. Oncol. Hematol. 67, 103–112 (2008).
  Article PubMed Google Scholar
• Agarwal, R. & Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Rev. Cancer 3, 502–516 (2003).
  Article CAS Google Scholar
• Balvert-Locht, H. R. et al. Improved prognosis of ovarian cancer in the Netherlands during the period 1975–1985: a registry-based study. Gynecol. Oncol. 42, 3–8 (1991).
  Article CAS PubMed Google Scholar
• Mutch, D. G. Surgical management of ovarian cancer. Semin. Oncol. 29, 3–8 (2002).
  Article PubMed Google Scholar
• Ozols, R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194–3200 (2003). A key study that confirmed the role of paclitaxel and carboplatin in ovarian cancer treatment.
  Article CAS PubMed Google Scholar
• du Bois, A., Neijt, J. P. & Thigpen, J. T. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer — a new standard of care? Ann. Oncol. 10 (Suppl. 1), 35–41 (1999).
  Article PubMed Google Scholar
• Biagi, J. J. & Eisenhauer, E. A. Systemic treatment policies in ovarian cancer: the next 10 years. Int. J. Gynecol. Cancer 13 (Suppl. 2), 231–240 (2003).
  Article PubMed Google Scholar
• Neijt, J. P. et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18, 3084–3092 (2000).
  Article CAS PubMed Google Scholar
• Sandercock, J., Parmar, M. K., Torri, V. & Qian, W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br. J. Cancer 87, 815–824 (2002). An important editorial that raises questions about the extent of benefit of paclitaxel and carboplatin over single-agent carboplatin.
  Article CAS PubMed PubMed Central Google Scholar
• Greenlee, R. T., Hill-Harmon, M. B., Murray, T. & Thun, M. Cancer statistics, 2001. CA Cancer J. Clin. 51, 15–36 (2001).
  Article CAS PubMed Google Scholar
• Gore, M. E., Fryatt, I., Wiltshaw, E. & Dawson, T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36, 207–211 (1990). One of the first papers to describe the importance of the platinum-free interval following platinum-based treatment in ovarian cancer.
  Article CAS PubMed Google Scholar
• De Placido, S. et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol. 22, 2635–2642 (2004).
  Article CAS PubMed Google Scholar
• Bookman, M. A., Greer, B. E. & Ozols, R. F. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int. J. Gynecol. Cancer 13, 735–740 (2003).
  Article CAS PubMed Google Scholar
• Monk, B. J. et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubiciin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann. Oncol., 19, (Supp. 8), viii1–viii4 (2008).
  Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000). A key paper that describes the major therapeutic targets in cancer.
  Article CAS PubMed Google Scholar
• Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011–1027 (2005).
  Article CAS PubMed Google Scholar
• Martin, L. & Schilder, R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J. Clin. Oncol. 25, 2894–2901 (2007).
  Article CAS PubMed Google Scholar
• Ramakrishnan, S., Subramanian, I. V., Yokoyama, Y. & Geller, M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8, 169–182 (2005).
  Article CAS PubMed Google Scholar
• Burger, R. A. Experience with bevacizumab in the management of epithelial ovarian cancer. J. Clin. Oncol. 25, 2902–2908 (2007). One of the first detailed reviews of this new treatment.
  Article CAS PubMed Google Scholar
• Nagy, J. A., Meyers, M. S., Masse, E. M., Herzberg, K. T. & Dvorak, H. F. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res. 55, 369–375 (1995).
  CAS PubMed Google Scholar
• Yoshiji, H. et al. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 33, 841–847 (2001).
  Article CAS PubMed Google Scholar
• Spannuth, W. A., Sood, A. K. & Coleman, R. L. Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clin. Pract. Oncol. 5, 194–204 (2008). An excellent recent review of this topic.
  Article CAS Google Scholar
• Mesiano, S., Ferrara, N. & Jaffe, R. B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 153, 1249–1256 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Gossmann, A. et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am. J. Obstet. Gynecol. 183, 956–963 (2000).
  Article CAS PubMed Google Scholar
• Hu, L. et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol. 161, 1917–1924 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Byrne, A. T. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9, 5721–5728 (2003).
  CAS PubMed Google Scholar
• Xu, L. et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol. 16, 445–454 (2000).
  CAS PubMed Google Scholar
• Machida, S. et al. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int. J. Cancer 114, 224–229 (2005).
  Article CAS PubMed Google Scholar
• Cannistra, S. A. et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180–5186 (2007).
  Article CAS PubMed Google Scholar
• Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E. & Sorosky, J. I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 5165–5171 (2007).
  Article CAS PubMed Google Scholar
• Han, E. S. & Monk, B. J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol. Oncol. 105, 3–6 (2007).
  Article CAS PubMed Google Scholar
• Kaye, S. B. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J. Clin. Oncol. 25, 5150–5152 (2007).
  Article CAS PubMed Google Scholar
• Tew, W. P. et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J. Clin. Oncol. 25 (Suppl.), 5508 (2007).
  Google Scholar
• Biagi, J. J. et al. A phase II study of sunitinib (SU11248) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma - NCIC GTG IND 185. J. Clin. Oncol. 26, (Suppl.), 5522 (2008).
  Article Google Scholar
• Friedlander, M. et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. J. Clin. Oncol. 25 (Suppl.), 5561 (2007).
  Google Scholar
• Hirte, H. W. et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J. Clin. Oncol. 26 (Suppl.), 5521 (2008).
  Article Google Scholar
• Matei, D., Sill, M. W., De Geest, K. & Bristow, R. E. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol. 26 (Suppl.), 5537 (2008).
  Article Google Scholar
• Matulonis, U. A. et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J. Clin. Oncol. 26 (Suppl.), 5501 (2008).
  Article Google Scholar
• Fukumura, D. & Jain, R. K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 101, 937–949 (2007).
  Article CAS PubMed Google Scholar
• Hu, L. et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. 11, 6966–6971 (2005).
  Article CAS PubMed Google Scholar
• Garofalo, A. et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin. Cancer Res. 9, 3476–3485 (2003).
  CAS PubMed Google Scholar
• Naumova, E. et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Res. 12, 1839–1849 (2006).
  Article CAS PubMed Google Scholar
• Zhong, X. et al. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int. J. Oncol. 25, 445–451 (2004).
  CAS PubMed Google Scholar
• Azad, N. S. et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26, 3709–3714 (2008). One of the first studies describing the challenges associated with combinations of targeted treatments.
  Article CAS PubMed Google Scholar
• Nimeiri, H. S. et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol. 110, 49–55 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Nathan, P. et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J. Clin. Oncol. 26 (Suppl.), 3550 (2008).
  Article Google Scholar
• Shaked, Y. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785–1787 (2006).
  Article CAS PubMed Google Scholar
• Schilder, R. J. et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 26, 3418–3425 (2008).
  Article CAS PubMed Google Scholar
• Henriksen, R. et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 53, 4550–4554 (1993).
  CAS PubMed Google Scholar
• Matei, D. et al. Autocrine activation of PDGFRα promotes the progression of ovarian cancer. Oncogene 25, 2060–2069 (2006).
  Article CAS PubMed Google Scholar
• Alberts, D. S. et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int. J. Gynecol. Cancer 17, 784–788 (2007).
  Article CAS PubMed Google Scholar
• Coleman, R. L. et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol. 101, 126–131 (2006).
  Article CAS PubMed Google Scholar
• Matei, D. et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 113, 723–732 (2008).
  Article CAS PubMed Google Scholar
• Posadas, E. M. et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110, 309–317 (2007).
  Article CAS PubMed Google Scholar
• Matei, D., Chang, D. D. & Jeng, M. H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin. Cancer Res. 10, 681–690 (2004).
  Article CAS PubMed Google Scholar
• Jayson, G. C. et al. Blockade of platelet-derived growth factor receptor-β by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 23, 973–981 (2005).
  Article CAS PubMed Google Scholar
• Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Bartlett, J. M. et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 73, 301–306 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Fischer-Colbrie, J. et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 17, 613–619 (1997).
  CAS PubMed Google Scholar
• Sirotnak, F. M. Studies with ZD1839 in preclinical models. Semin. Oncol. 30, 12–20 (2003).
  Article CAS PubMed Google Scholar
• Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I. & Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885–4892 (2000).
  CAS PubMed Google Scholar
• Ciardiello, F. et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053–2063 (2000).
  CAS PubMed Google Scholar
• Schilder, R. J. et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11, 5539–5548 (2005).
  Article CAS PubMed Google Scholar
• Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A. & Horowitz, I. R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21, 283–290 (2003).
  Article CAS PubMed Google Scholar
• Kaye, S. B. et al. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy wiht pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. J. Clin. Oncol. 26 (Suppl.), 5520 (2008).
  Article Google Scholar
• Amler, L. et al. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 26 (Suppl.), 5552 (2008).
  Article Google Scholar
• Elnakat, H. & Ratnam, M. Role of folate receptor genes in reproduction and related cancers. Front. Biosci. 11, 506–519 (2006).
  Article CAS PubMed Google Scholar
• Kalli, K. R. et al. Folate receptor α as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108, 619–626 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Ebel, W. et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-α. Cancer Immun. 7, 6 (2007).
  PubMed PubMed Central Google Scholar
• Armstrong, D. et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor-α, in platinum-sensitive ovarian cancer in first relapse. J. Clin. Oncol. 26 (Suppl.), 5500 (2008).
  Article Google Scholar
• Gibbs, D. D. et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors. Cancer Res. 65, 11721–11728 (2005).
  Article CAS PubMed Google Scholar
• Ame, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882–893 (2004).
  Article CAS PubMed Google Scholar
• Dantzer, F. et al. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 39, 7559–7569 (2000).
  Article CAS PubMed Google Scholar
• Tutt, A. N. et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 139–148 (2005).
  Article CAS PubMed Google Scholar
• Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864–5874 (2006).
  Article CAS PubMed Google Scholar
• Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785–3790 (2008). An excellent recent review of PARP inhibitors.
  Article CAS PubMed Google Scholar
• Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
  Article CAS PubMed Google Scholar
• Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005). References 79 and 80 describe the basis of this new approach for the first time.
  Article CAS PubMed Google Scholar
• Fong, P. C. et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J. Clin. Oncol. 24 (Suppl.), 3022 (2006).
  Google Scholar
• Yap, T. A. et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J. Clin. Oncol. 25 (Suppl.), 3529 (2007).
  Google Scholar
• Fong, P. C. et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J. Clin. Oncol. 26 (Suppl.), 5510 (2008).
  Article Google Scholar
• Carden, C. et al. A Phase I study of AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor: results in patients with BRCA deficient ovarian cancer (BDOC). Abst. BOA22, 320. (National Cancer Research Institute Cancer Conference, 2008].
• Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Rev. Cancer 4, 814–819 (2004).
  Article CAS Google Scholar
• McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).
  Article CAS PubMed Google Scholar
• Press, J. Z. et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 606–619 (2006).
  Article CAS PubMed Google Scholar
• Hu, L., Hofmann, J. & Jaffe, R. B. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin. Cancer Res. 11, 8208–8212 (2005).
  Article CAS PubMed Google Scholar
• Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
  Article CAS Google Scholar
• Yap, T. A. et al. Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393–412 (2008).
  Article CAS PubMed Google Scholar
• Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. & Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev. Drug Discov. 4, 988–1004 (2005). An excellent review of this important topic.
  Article CAS Google Scholar
• Lopiccolo, J., Blumenthal, G. M., Bernstein, W. B. & Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32–50 (2008).
  Article CAS PubMed Google Scholar
• Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21, 99–102 (1999).
  Article CAS PubMed Google Scholar
• Levine, D. A. et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11, 2875–2878 (2005).
  Article CAS PubMed Google Scholar
• Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678–7681 (2004).
  Article CAS PubMed Google Scholar
• Philp, A. J. et al. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426–7429 (2001).
  CAS PubMed Google Scholar
• Trotman, L. C. & Pandolfi, P. P. PTEN and p53: who will get the upper hand? Cancer Cell 3, 97–99 (2003).
  Article CAS PubMed Google Scholar
• Obata, K. et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58, 2095–2097 (1998).
  CAS PubMed Google Scholar
• Jiang, B. H. & Liu, L. Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim. Biophys. Acta 1784, 150–158 (2008).
  Article CAS PubMed Google Scholar
• Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H. & Nicosia, S. V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24, 7482–7492 (2005).
  Article CAS PubMed Google Scholar
• Page, C. et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20, 407–416 (2000).
  CAS PubMed Google Scholar
• Hu, L., Hofmann, J., Lu, Y., Mills, G. B. & Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087–1092 (2002).
  CAS PubMed Google Scholar
• Yang, X., Fraser, M., Moll, U. M., Basak, A. & Tsang, B. K. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 66, 3126–3136 (2006).
  Article CAS PubMed Google Scholar
• Arboleda, M. J. et al. Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63, 196–206 (2003).
  CAS PubMed Google Scholar
• Yuan, Z. Q. et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19, 2324–2330 (2000).
  Article CAS PubMed Google Scholar
• Cheng, J. Q. et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl Acad. Sci. USA 89, 9267–9271 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Bellacosa, A. et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280–285 (1995).
  Article CAS PubMed Google Scholar
• Nakayama, K. et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 5, 779–785 (2006).
  Article CAS PubMed Google Scholar
• Carpten, J. D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439–444 (2007).
  Article CAS PubMed Google Scholar
• Oza, A. et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J. Clin. Oncol. 26 (Suppl.), 5516 (2008).
  Article Google Scholar
• Slomovitz, B. et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). J. Clin. Oncol. 26 (Suppl.), 5502 (2008).
  Article Google Scholar
• Wiener, J. R. et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol. Oncol. 88, 73–79 (2003).
  Article CAS PubMed Google Scholar
• Dressman, H. K. et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25, 517–525 (2007). An important paper that highlights the role of the oncogene SRC in ovarian cancer.
  Article CAS PubMed Google Scholar
• Yu, K., Toral-Barza, L., Shi, C., Zhang, W. G. & Zask, A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol. Ther. 7, 307–315 (2008).
  PubMed Google Scholar
• Tan, D.S. et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin. Cancer Res. (in the press).
• Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Rev. Cancer 8, 755–768 (2008).
  Article CAS Google Scholar
• Szotek, P. P. et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc. Natl Acad. Sci. USA 103, 11154–11159 (2006). An important paper confirming the existence of cancer stem cells in ovarian cancer.
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311–4320 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Workman, P. & Kaye, S. B. Translating basic cancer research into new cancer therapeutics. Trends Mol. Med. 8, S1–S9 (2002).
  Article PubMed Google Scholar
• Futreal, P. A. et al. Cancer and genomics. Nature 409, 850–852 (2001).
  Article CAS PubMed Google Scholar
• Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
  Article CAS PubMed Google Scholar
• Venter, J. C. et al. The sequence of the human genome. Science 291, 1304–1351 (2001).
  Article CAS PubMed Google Scholar
• Thomas, G. V. mTOR and cancer: reason for dancing at the crossroads? Curr. Opin. Genet. Dev. 16, 78–84 (2006).
  Article CAS PubMed Google Scholar
• Banerji, U., de Bono, J., Judson, I., Kaye, S. & Workman, P. Biomarkers in early clinical trials: the committed and the skeptics. Clin. Cancer Res. 14, 2512 (2008).
  Article PubMed Google Scholar
• Workman, P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther. 2, 131–138 (2003).
  Article CAS PubMed Google Scholar
• Workman, P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr. Pharm. Des. 9, 891–902 (2003).
  Article CAS PubMed Google Scholar
• Sarker, D. & Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 96, 213–268 (2007).
  Article CAS PubMed Google Scholar
• Srinivasan, M., Sedmak, D. & Jewell, S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 161, 1961–1971 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, J. M. et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin. Cancer Res. 14, 1938–1946 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, J. K. et al. A novel technique for the enrichment of primary ovarian cancer cells. Am. J. Obstet. Gynecol. 197, 507 e1–e5 (2007).
  Article Google Scholar
• Barker, S. D. et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol. Oncol. 82, 57–63 (2001).
  Article CAS PubMed Google Scholar
• Provencher, D. M. et al. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol. Oncol. 50, 78–83 (1993).
  Article CAS PubMed Google Scholar
• Puiffe, M. L. et al. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9, 820–829 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Forster, M. D., Ormerod, M. G., Agarwal, R., Kaye, S. B. & Jackman, A. L. Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells. Cytometry A 71, 945–950 (2007).
  Article PubMed Google Scholar
• Pantel, K., Brakenhoff, R. H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Rev. Cancer 8, 329–340 (2008).
  Article CAS Google Scholar
• Marth, C., Kisic, J., Kaern, J., Trope, C. & Fodstad, O. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer 94, 707–712 (2002).
  Article PubMed Google Scholar
• Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Sessa, C. et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23, 1867–1874 (2005).
  Article CAS PubMed Google Scholar
• Krasner, C. N. et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br. J. Cancer 97, 1618–1624 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• del Campo, J. et al. Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J. Clin. Oncol. 24 (Suppl.), 5031 (2006).
  Google Scholar
• Smit, W. M. et al. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. J. Clin. Oncol. 23 (Suppl.), 5056 (2005).
  Article Google Scholar
• Forster, M. et al. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin. Cancer Res. 13, 4178–4184 (2007).
  Article CAS PubMed Google Scholar
• Kavanagh, J. J. et al. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1–1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int. J. Gynecol. Cancer 15, 593–600 (2005).
  CAS PubMed Google Scholar
• Rose, P. et al. Canfosfamide (C, TLK286) plus carboplatin (P) vs. liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC): phase 3 study results. J. Clin. Oncol. 25 (Suppl.), 5529 (2007).
  Google Scholar
• Vergote, I. et al. Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd line treatment of platinum (P) refractory or resistant ovarian cancer (OC): phase 3 study results. J. Clin. Oncol. 25 (Suppl.), 5528 (2007).
  Google Scholar
• Garcia, A. A. et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26, 76–82 (2008).
  Article CAS PubMed Google Scholar
• McGonigle, K. F. et al. A phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian or peritoneal cancer. J. Clin. Oncol. 26 (Suppl.), 5551 (2008).
  Article Google Scholar
• Micha, J. P. et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int. J. Gynecol. Cancer 17, 771–776 (2007).
  Article CAS PubMed Google Scholar
• Campos, S. M. et al. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. J. Clin. Oncol. 25 (Suppl.), 5517 (2007).
  Google Scholar
• Posadas, E. M. et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109, 1323–1330 (2007).
  Article CAS PubMed Google Scholar
• Slomovitz, B. M. et al. Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. J. Clin. Oncol. 24 (Suppl.), 5090 (2006).
  Google Scholar
• Pautier, F. et al. Gefitinib in combination with paclitaxel and carboplatin as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: final results of a phase II study. J. Clin. Oncol. 25 (Suppl.), 5566 (2007).
  Google Scholar
• Wagner, U. et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy — a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol. Oncol. 105, 132–137 (2007).
  Article CAS PubMed Google Scholar
• Gordon, A. N. et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int. J. Gynecol. Cancer 15, 785–792 (2005).
  Article CAS PubMed Google Scholar
• Vasey, P. A. et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br. J. Cancer 98, 1774–1780 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Blank, S. V. et al. Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer. J. Clin. Oncol. 24 (Suppl.), 5076 (2006).
  Google Scholar
• Schilder, R. J. et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol. 21 Jan 2009 (doi:10.1016/j.ygyno.2008.12.003).
• Konner, J. et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol. Oncol. 110, 140–145 (2008).
  Article CAS PubMed Google Scholar
• Secord, A. A. et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol. Oncol. 108, 493–499 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Seiden, M. V. et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol. Oncol. 104, 727–731 (2007).
  Article CAS PubMed Google Scholar
• Gordon, M. S. et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24, 4324–4332 (2006).
  Article CAS PubMed Google Scholar
• Rivkin, S. E. et al. Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients. J. Clin. Oncol. 26 (Suppl.), 5556 (2008).
  Article Google Scholar
• Campos, S. et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J. Clin. Oncol. 23, 5597–5604 (2005).
  Article CAS PubMed Google Scholar
• Armstrong, D. K. et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor-α, in platinum-sensitive ovarian cancer in first relapse. J. Clin. Oncol. 26, 1 (2008).
  Google Scholar